Logan Lutton

Here’s what you missed this week on Managed Healthcare Executive.

The Residual Transformer Generative Adversarial Network (RRTGAN) generates high-quality, cellular-level retinal images from minimal data inputs, overcoming the limitations of previous slow and burdensome imaging methods.

Kyverna’s investigational CAR-T therapy, mivocabtagene autoleucel (miv-cel) showed clinically meaningful mobility improvements in most stiff-person syndrome patients, prompting the company to plan an FDA BLA submission in 2026.

Falls among older adults with visual impairment are strongly linked to modifiable home hazards—especially broken flooring and tripping risks—while fall risk remains relatively low in hazard-free homes.

Despite widespread awareness of shingles risk factors, fewer than one-third of U.S. primary care physicians are fully aware of current ACIP shingles vaccine recommendations, highlighting the need for improved education and implementation.

A new influenza strain could fuel a severe flu season while a surge in measles cases threatens U.S. elimination status, emphasizing that vaccination remains critical to limiting disease spread and severity, according to faculty from Johns Hopkins Bloomberg School of Public Health.

Addyi is the first FDA-approved treatment for low libido in women ages 65 and younger.

A study of more than 1 million UK medical records found that getting a flu vaccine between ages 40 and 50 did not increase Parkinson’s disease risk and was even associated with a lower estimated prevalence eight years later, suggesting a possible protective effect that warrants further research.

Results from a recent ianalumab treatment trial signal a potential for longer-lasting disease control for patients with primary immune thrombocytopenia.

The CAR T Vision Steering Committee members wish to double the number of eligible patients receiving chimeric antigen receptor (CAR) T-cell therapy by 2030 through disease awareness and sustainable financing options, according to George Eastwood, Executive Director of the Emily Whitehead Foundation and recent CAR T Vision Steering Committee member.

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of awareness around the therapy are barriers to care, according to George Eastwood, Executive Director of the Emily Whitehead Foundation.

In this interview, George Eastwood, Executive Director of the Emily Whitehead Foundation and CAR T Vision steering committee member discusses barriers and strategies for expanding access to CAR T-cell therapy.

Here’s what you missed this week on Managed Healthcare Executive.

About one-third of families with a child undergoing treatment for acute lymphoblastic leukemia experienced catastrophic income loss during therapy, with many developing new material hardships over the two-year course, underscoring the need for ongoing financial screening and support.

IV iron infusions were found to be safe for anemic patients hospitalized with acute bacterial infections and were associated with improved survival and higher hemoglobin levels, challenging long-held concerns that iron worsens infections.

Multiple sclerosis patients who completed hydrotherapy courses had better symptom outcomes than patients who participated in physical therapy sessions on land.

Self-administered clinical hypnosis cut hot flash frequency and severity by more than 50% in postmenopausal women, showing effectiveness comparable to therapist-led treatment in a recent randomized trial.

In this interview, Susan Kellogg-Spadt, Ph.D., the director of female sexual medicine at the Center for Pelvic Medicine at Academic Urology of PA, discusses common menopausal sexual issues and how the culture around ageism and taboo is changing.

In lupus patients, latent Epstein-Barr virus can reprogram B cells and send the body’s immune response into overdrive, resulting in widespread inflammation.

World AIDS Day highlights ongoing challenges in HIV prevention and treatment, urging renewed commitment to end the epidemic and support affected communities.

A new report reveals the heavy personal and economic toll of MS and recommends more complete, patient focused approaches to measuring and managing the disease.

Telehealth mostly replaces in-person visits, with a 74% substitution rate, indicating lower federal costs and sustained value beyond the pandemic.

Nicotine dependency is a worldwide health threat, especially for HIV patients, who are more likely to smoke and to have health complications than healthy patients.

Here’s what you missed this week on Managed Healthcare Executive.

This year marks the fifth consecutive year Independence Blue Shield has received high marks for their Medicare plans.

The results of a new Kinsey Institute study show that masturbation eased menopause symptoms for a significant number of women, yet few clinicians discuss it, despite strong interest from patients.

The American Gastroenterological Association has released updated guidelines for treating moderate-to-severe Crohn’s disease, outlining 16 evidence-based recommendations that prioritize advanced therapies and reflect new medication approvals since 2021.

Health benefit costs for employees are projected to rise 6.7% in 2026—the largest increase in 15 years—as employers grapple with escalating prescription drug prices, growing GLP-1 coverage and a broader push to offer diverse, cost-saving health plan options amid mounting affordability concerns.

Medicaid expansion increased overall PrEP access in the U.S., but significant racial, gender and structural disparities persist, limiting equitable HIV prevention despite rising national uptake.

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States under a restricted-distribution program because of the drug’s risk of progressive multifocal leukoencephalopathy.